Reports
Sale
Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market: By Drug Type: Corticosteroids, Immunoglobulin, Others; By Route of Administration: Injectable, Oral; By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Others; Regional Analysis; Competitive Landscape: Industry Events and Developments; 2024-2032
Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Outlook
The global chronic inflammatory demyelinating polyneuropathy therapeutics market is expected to grow in the forecast period of 2024-2032 at a CAGR of 6.60%.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Demand for Corticosteroids is Driving the Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Industry
Corticosteroids reduce inflammation and hamper the efficiency of the immune system and are known to improve the health of around 60% of the patients. Hence, this drug type is witnessing a significant demand in the healthcare industry. In addition to this, these drugs are easy to administer, relatively cheap as compared to their counterparts, and offer long term remission in chronic inflammatory demyelinating polyneuropathy therapeutics.
The response rate of corticosteroids is high, which is anticipated to be a major driving factor of the segment in the forecast period. In the coming years, the anticipated increase in demand for corticosteroids such as prednisone and prednisolone, as orally taken tablets, is likely to provide impetus to the segment.
North America Currently Holds a Sizable Share in the Market for Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics
The chronic inflammatory demyelinating polyneuropathy therapeutics market in the North America region is being driven by the technologically advanced healthcare infrastructure present in the United States and Canada. A significant portion of the American population gets affected by chronic inflammatory demyelinating polyneuropathy (CIDP) every year. Favourable policies of the government along with social media campaigns spreading awareness about CIDP are likely to add to the market growth in the coming years.
Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Chronic inflammatory demyelinating polyneuropathy or CIDP is defined as an auto-immune disorder in which the own immune system of a person’s attacks myelin, which protects the body’s nerves. Chronic inflammatory demyelinating polyneuropathy therapeutics is a treatment which aims at providing comfort to the patients during this disorder through medicines and drugs.
Based on drug type, the market can be segmented into:
- Corticosteroids
- Immunoglobulin
- Others
By route of administration, the chronic inflammatory demyelinating polyneuropathy therapeutics market has been divided into:
- Injectable
- Oral
On the basis of distribution channel, the market has been segmented into:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Increasing Prevalence of CIDP to Boost the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Industry
The increasing prevalence of chronic inflammatory demyelinating polyneuropathy, owing to the rising cases of diabetes and cancer, among others, is driving the demand for CIDP therapeutics. In addition, the market is being positively navigated by the rise in geriatric population and sedentary lifestyles led by the working-class adults.
Over the forecast period, the anticipated increase in spending by the government of emerging economies on bolstering the neurological treatment infrastructure are likely to accelerate the demand for CIDP therapeutics. Moreover, the market is anticipated to be aided by the growing FDA approvals of immunoglobulin CDIP therapeutics which is accelerating the production of CDIP drugs. Strategic collaborations between pharmaceutical laboratories aimed towards providing high-quality CDIP therapeutics are anticipated to provide impetus to growth of the market in the coming years.
Key Players in the Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market
The report gives a detailed analysis of the following key players in the chronic inflammatory demyelinating polyneuropathy therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- CSL Behring
- GeNeuro SA
- ADMA Biologics, Inc.
- Pfizer Inc.
- UCB S.A
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Type |
|
| Breakup by Route of Administration |
|
| Breakup by Distribution Channel |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Application
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
8.1 Key Industry Highlights
8.2 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market (2018-2023)
8.3 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast (2024-2032)
8.4 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market by Drug Type
8.4.1 Corticosteroids
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.2 Immunoglobulin
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Others
8.5 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market by Route of Administration
8.5.1 Injectable
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Oral
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.6 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market by Distribution Channel
8.6.1 Hospital Pharmacy
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Online Pharmacy
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Retail Pharmacy
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.7 Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 CSL Behring
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 ADMA Biologics, Inc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 Pfizer Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 GeNeuro SA
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 UCB S.A
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market: Key Industry Highlights, 2018 and 2032
2. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Drug Type (USD Million), 2018-2023
3. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Drug Type (USD Million), 2024-2032
4. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Route of Administration (USD Million), 2018-2023
5. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Route of Administration (USD Million), 2024-2032
6. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
7. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
8. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Structure
Key Questions Answered in the Report
In 2021, the global CIDP therapeutics market attained a value of nearly USD xx billion.
The market is estimated to grow at a CAGR of 6.60% between 2024 and 2032.
The market is estimated to witness a healthy growth in the forecast period of 2024-2032, encouraged by the various industry drivers.
The major regions in the market for CIDP therapeutics are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The major drivers of the market include the increasing prevalence of chronic inflammatory demyelinating polyneuropathy, growing geriatric population, and increasing CIDP treatment production capacity of pharmaceutical firms.
The increasing efforts by the government aimed towards bolstering the neurological treatment infrastructure in the emerging economies are likely to be the key trends in the market.
Corticosteroids, and immunoglobulin, among others are the different drug types based on which the market has been divided.
Injectable and oral are the segments based on route of administration.
Hospital pharmacy, online pharmacy, and retail pharmacy are the significant distribution channels identified in the market report.
The major players in the industry are CSL Behring, ADMA Biologics, Inc., Pfizer Inc., GeNeuro SA, and UCB S.A, among others.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER